Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma

Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and malignant mesothelioma, employ noninvasive application of low-intensity, intermediate-frequency, alternating electric fields to disrupt the mitotic spindle, leading to chromosome missegregation and apoptosis. Emerging e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dongjiang, Le, Son B., Hutchinson, Tarun E., Calinescu, Anda-Alexandra, Sebastian, Mathew, Jin, Dan, Liu, Tianyi, Ghiaseddin, Ashley, Rahman, Maryam, Tran, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012294/
https://www.ncbi.nlm.nih.gov/pubmed/35199647
http://dx.doi.org/10.1172/JCI149258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012294/
https://www.ncbi.nlm.nih.gov/pubmed/35199647
http://dx.doi.org/10.1172/JCI149258

Ejemplares similares